The Cybersecurity Void In Mexico Why Your FDA-Compliant Device Might Still Fail
The Cybersecurity Void In Mexico Why Your FDA-Compliant Device Might Still Fail
Publish Date: 2026-02-20 00:00:00
Source Domain: www.meddeviceonline.com
By Julio G. Martinez-Clark, CEO, bioaccess
For medical device manufacturers, the global cybersecurity landscape is usually defined by strict codified mandates: the FDA’s Section 524B, the EU’s MDR, and recently, Brazil’s RDC 657/2022. Against this backdrop of rigorous enforcement, Mexico often appears as a welcome anomaly — a low-friction market where Software as a Medical Device (SaMD) is barely regulated and entry barriers are falling.
However, this regulatory silence is a commercial trap. While Mexico’s health authority, COFEPRIS, has streamlined registration, a dangerous shadow regulation has emerged in the public procurement sector. Driven by a surge in ransomware attacks, buyers like the Mexican Institute of Social Security (IMSS) and the Institute for Social Security and Services for State Workers (ISSSTE) are imposing ad hoc stringent cybersecurity requirements in tenders that catch even the most compliant global manufacturers off guard.
The Regulatory Mirage: Access Has Never Been Easier
On paper, Mexico is currently one of the most accessible markets for medical devices in Latin America. Effective September 1, 2025, COFEPRIS introduced a new Abbreviated Regulatory Pathway, allowing manufacturers to leverage approvals from the FDA, Health Canada, and other IMDRF members to secure registration in as little as 30 days.¹
Furthermore, unlike Brazil’s ANVISA, which enforced Resolution RDC 657/2022 to mandate specific cybersecurity architecture and documentation for SaMD, COFEPRIS still lacks a specific comprehensive regulation for medical software.² For a regulatory affairs director, this looks like an easy win: fast approval with minimal technical documentation required for the software components.
The Commercial Reality: The Shadow Regulator
The disconnect occurs when the device moves from registration to procurement. In the absence of federal guidance, Mexican public healthcare institutions — which purchase the vast…
